Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2023 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater...
December 11, 2022 10:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
November 10, 2022 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
October 04, 2022 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
July 01, 2022 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
June 28, 2021 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has...
May 17, 2021 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
March 30, 2021 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
March 04, 2021 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
January 28, 2021 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...

Next Page keyboard_arrow_right